Share this article
Share this article
DUBLIN, April 27, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy. The study will evaluate intravenously administered (IV) nemvaleukin in patients with mucosal melanoma and subcutaneously administered (SC) nemvaleukin in patients with advanced cutaneous melanoma. Nemvaleukin, Alkermes lead immuno-oncology candidate, is a novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy. Nemvaleukin was granted orphan drug designation for the treatment of mucosal melanoma by the U.S. Food and Drug Administration (FDA) in March 2021.
Bugworks secures funding from US Government s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
News provided by
Share this article
Share this article
BANGALORE, India, April 26, 2021 /PRNewswire/ Bugworks Research, Inc ( Bugworks ), secures funding from the Defense Threat Reduction Agency (DTRA) to support development of its novel broad-spectrum antibiotic BWC0977, against the most critical bacterial biothreats.
DTRA will provide funding, through its Bacterial Rapid Acquisition Platform program, to support the nonclinical biodefense aspects of the development of BWC0977, including execution of in vivo efficacy studies to test BWC0977 against biothreat bacterial pathogens, beginning with
Glenmark s Ryaltris® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age
News provided by
Share this article
Share this article
The launch will ensure much-needed access to a novel fixed-dose combination nasal spray for this chronic condition
This marks Glenmark s first innovative product approval in the European Union
MUMBAI, India, April 26, 2021 /PRNewswire/ Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union. Ryaltris
Mediso completes technology transfer of novel MRI spectrometer
News provided by
Share this article
Share this article
BUDAPEST, Hungary, April 26, 2021 /PRNewswire/ Mediso Medical Imaging Systems today announced that it has completed the technology transfer of the new Cameleon4™ MRI spectrometer developed by RS
2D (Strasbourg, France). Following the IP transfer, the new console is seamlessly integrated into the nanoScan
® cryogen-free 3T and 7T MRI product line resulting in superior imaging performance. Financial terms of the agreement were not disclosed. Mediso nanoScan® PET/MRI 7T
For the past seven years Mediso and RS
2D partnered in a technology license and commercial agreement to deliver the new line of nanoScan
Share this article
Share this article
ResearchAndMarkets.com s offering.
2021 Healthcare Law Firm Hourly Rate Report is the most comprehensive and most detailed competitive intelligence and legal pricing tool available because the Report details average hourly rates by individual law firms as opposed to aggregate groupings of law firms with disparate pricing structures as is found in surveys, peer services and e-billing reports.
The report analyzes and presents hourly rates for 2016 - 2021 by Firm, Position (Senior Partner, Partner, Counsel, Senior Associate, Associate and Support Staff) and all key practice areas in healthcare. Additionally, the report lists the buying clients (mainly large corporations).